VTVT (vTv Therapeutics) Earnings per share for the last four quarters

vTv Therapeutics Inc. (VTVT) automates the creation of anti-diabetes molecules via biocomputer algorithms, operating in a promising market with a colossal patient base where growth is constrained only by strict regulatory standards. This chart of shares on GURU.Markets demonstrates an EPS TTM of 81.40. The application of AI and robotics accelerates pill synthesis, although final drug trials still require medical supervision.
VTVT (vtvtherapeutics.com): analytical breakdowns and indicator data

The development dynamics of innovative drugs by vTv Therapeutics Inc. (VTVT) for the treatment of type 1 diabetes are reflected in the current EPS YoY TTM growth rate. This indicator measures the annual change in net income per share over a rolling twelve-month period, where daily recalculations eliminate reporting time lags, allowing investors to promptly assess capital resilience against market downturns.